Guro Fannelb Giskedegrd1, Steinar Lundgren1,2, Beathe Sitter1, Hans Fjsne3, Jostein Halgunset4, David E. Axelson5, Ingrid Susann Gribbestad1, Tone Frost Bathen1
1Dept. of Circulation and Medical Imaging, Norwegian University of Science and Technology (NTNU), Trondheim, Norway; 2Dept. of Oncology, St. Olavs University Hospital, Trondheim, Norway; 3Dept. of Surgery, St. Olavs University Hospital, Trondheim, Norway; 4Dept. of Laboratory Medicine, Children's and Women's Health, NTNU, Trondheim, Norway; 5MRi_Consulting, Kingston, Canada
Predicting prognostic factors of breast cancer is important for clinical decision-making. The purpose of this study was to predict lymphatic spread and ER status of breast cancer patients using MR metabolomics, and to classify the patients according to these factors. HR MAS MR spectra of tumor tissue from breast cancer patients were obtained and further analysed by PLS and BBN. PLS analysis clustered the spectra according to lymphatic spread and ER status, and both PLS and BBN could predict the status of spectra from blind samples. MR metabolomics may thus be a tool to identify subclasses of breast cancer patients related to prognosis and outcome.